You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGuanfacine
Accession NumberDB01018  (APRD00075)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]
Structure
Thumb
Synonyms
Estulic
Guanfacina
Guanfacinum
External Identifiers
  • SPD 503
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Intunivtablet, extended release1 mg/1oralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivProlonged-release tablet2 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivProlonged-release tablet3 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivkitShire US Manufacturing Inc.2009-09-02Not applicableUs
Intunivtablet, extended release2 mg/1oralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivProlonged-release tablet2 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intunivtablet, extended release1 mg/1oralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivProlonged-release tablet4 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivProlonged-release tablet2 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intunivtablet, extended release3 mg/1oralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivProlonged-release tablet1 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intunivtablet, extended release2 mg/1oralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivProlonged-release tablet4 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
IntunivProlonged-release tablet3 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intunivtablet, extended release4 mg/1oralShire US Manufacturing Inc.2009-09-02Not applicableUs
IntunivProlonged-release tablet1 mgOral useShire Pharmaceuticals Ireland Ltd2015-09-17Not applicableEu
Intuniv XRtablet (extended-release)1 mgoralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRtablet (extended-release)3 mgoralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRtablet (extended-release)2 mgoralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Intuniv XRtablet (extended-release)4 mgoralShire Pharma Canada Ulc2013-08-06Not applicableCanada
Tenextablet1 mg/1oralPromius Pharma, LLC1986-10-27Not applicableUs
Tenextablet2 mg/1oralPromius Pharma, LLC1986-10-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Guanfacinetablet, extended release4 mg/1oralActavis Pharma, Inc.2014-12-01Not applicableUs
Guanfacinetablet1 mg/1oralCardinal Health1997-01-27Not applicableUs
Guanfacinetablet, extended release1 mg/1oralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
Guanfacinetablet, extended release3 mg/1oralAv Kare, Inc.2015-07-07Not applicableUs
Guanfacinetablet1 mg/1oralREMEDYREPACK INC.2016-01-13Not applicableUs
Guanfacinetablet2 mg/1oralActavis Pharma, Inc.1995-10-17Not applicableUs
Guanfacinetablet2 mg/1oralPhysicians Total Care, Inc.2003-07-31Not applicableUs
Guanfacinetablet, extended release1 mg/1oralActavis Pharma, Inc.2014-12-01Not applicableUs
Guanfacinetablet1 mg/1oralGolden State Medical Supply, Inc.2014-04-22Not applicableUs
Guanfacinetablet, extended release2 mg/1oralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
Guanfacinetablet, extended release4 mg/1oralAv Kare, Inc.2015-07-07Not applicableUs
Guanfacinetablet1 mg/1oralMylan Pharmaceuticals Inc.1997-01-28Not applicableUs
Guanfacinetablet, extended release2 mg/1oralActavis Pharma, Inc.2014-12-01Not applicableUs
Guanfacinetablet1 mg/1oralPhysicians Total Care, Inc.1995-10-17Not applicableUs
Guanfacinetablet2 mg/1oralGolden State Medical Supply, Inc.2014-04-22Not applicableUs
Guanfacinetablet, extended release3 mg/1oralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
Guanfacinetablet1 mg/1oralEpic Pharma, LLC2013-12-02Not applicableUs
Guanfacinetablet2 mg/1oralMylan Pharmaceuticals Inc.1997-01-28Not applicableUs
Guanfacinetablet, extended release1 mg/1oralAv Kare, Inc.2015-07-07Not applicableUs
Guanfacinetablet, extended release3 mg/1oralActavis Pharma, Inc.2014-12-01Not applicableUs
Guanfacinetablet1 mg/1oralCardinal Health1995-10-17Not applicableUs
Guanfacinetablet, extended release4 mg/1oralTeva Pharmaceuticals USA Inc2015-06-02Not applicableUs
Guanfacinetablet2 mg/1oralEpic Pharma, LLC2013-12-02Not applicableUs
Guanfacinetablet1 mg/1oralActavis Pharma, Inc.1995-10-17Not applicableUs
Guanfacinetablet1 mg/1oralCarilion Materials Management1995-10-17Not applicableUs
Guanfacinetablet, extended release2 mg/1oralAv Kare, Inc.2015-07-07Not applicableUs
Guanfacine Extended-releasetablet, extended release1 mg/1oralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releasetablet, extended release4 mg/1oralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releasetablet, extended release2 mg/1oralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releasetablet, extended release1 mg/1oralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releasetablet, extended release3 mg/1oralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releasetablet, extended release2 mg/1oralSandoz Inc2015-06-03Not applicableUs
Guanfacine Extended-releasetablet, extended release4 mg/1oralPar Pharmaceutical Inc.2015-06-02Not applicableUs
Guanfacine Extended-releasetablet, extended release3 mg/1oralSandoz Inc2015-06-03Not applicableUs
Guanfacine Hydrochloridetablet1 mg/1oralAmneal Pharmaceuticals of New York, LLC1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet1 mg/1oralAv Kare, Inc.1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet, film coated, extended release4 mg/1oralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine Hydrochloridetablet, film coated, extended release1 mg/1oralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine Hydrochloridetablet2 mg/1oralAmneal Pharmaceuticals of New York, LLC1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet2 mg/1oralAv Kare, Inc.1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet1 mg/1oralMajor Pharmaceuticals1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet, film coated, extended release2 mg/1oralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine Hydrochloridetablet1 mg/1oralAmerican Health Packaging2014-05-30Not applicableUs
Guanfacine Hydrochloridetablet2 mg/1oralMajor Pharmaceuticals1998-11-25Not applicableUs
Guanfacine Hydrochloridetablet, film coated, extended release3 mg/1oralMylan Pharmaceuticals Inc.2015-06-02Not applicableUs
Guanfacine Hydrochloridetablet1 mg/1oralTYA Pharmaceuticals1998-11-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstulicEgis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Guanfacine Hydrochloride
Thumb
  • InChI Key: DGFYECXYGUIODH-UHFFFAOYSA-N
  • Monoisotopic Mass: 280.988945078
  • Average Mass: 282.554
DBSALT000509
Categories
UNII30OMY4G3MK
CAS number29110-47-2
WeightAverage: 246.093
Monoisotopic: 245.012267339
Chemical FormulaC9H9Cl2N3O
InChI KeyInChIKey=INJOMKTZOLKMBF-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
IUPAC Name
N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide
SMILES
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • 1,3-dichlorobenzene
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Guanidine
  • Carboxamide group
  • Carboximidamide
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
PharmacodynamicsGuanfacine is a phenylacetyl-guanidine derivative hypotensive and a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension.
Mechanism of actionGuanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects.
Related Articles
AbsorptionRapid and complete, with an oral bioavailability of approximately 80%.
Volume of distribution
  • 6.3 L/kg
Protein bindingApproximately 70% bound to plasma proteins, independent of drug concentration.
Metabolism

Hepatic

SubstrateEnzymesProduct
Guanfacine
3-hydroxyguanfacine glucuronideDetails
Route of eliminationIn individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine.
Half life17 hours (range 10-30 hours)
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD50=165mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9313
Blood Brain Barrier+0.9567
Caco-2 permeable-0.5101
P-glycoprotein substrateNon-substrate0.6778
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9833
Renal organic cation transporterNon-inhibitor0.6443
CYP450 2C9 substrateNon-substrate0.7572
CYP450 2D6 substrateNon-substrate0.7948
CYP450 3A4 substrateNon-substrate0.6475
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8893
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7376
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6619
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8107
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.7408 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.9285
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Amneal pharmaceutical
  • Mikah pharma llc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
  • Promius pharma llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral2 mg/1
Tablet, extended releaseoral1 mg/1
Tablet, extended releaseoral2 mg/1
Tablet, extended releaseoral3 mg/1
Tablet, extended releaseoral4 mg/1
Tablet, film coated, extended releaseoral1 mg/1
Tablet, film coated, extended releaseoral2 mg/1
Tablet, film coated, extended releaseoral3 mg/1
Tablet, film coated, extended releaseoral4 mg/1
Kit
Prolonged-release tabletOral use1 mg
Prolonged-release tabletOral use2 mg
Prolonged-release tabletOral use3 mg
Prolonged-release tabletOral use4 mg
Tablet (extended-release)oral1 mg
Tablet (extended-release)oral2 mg
Tablet (extended-release)oral3 mg
Tablet (extended-release)oral4 mg
Prices
Unit descriptionCostUnit
Intuniv 1 mg 24 Hour tablet5.72USD tablet
Intuniv 2 mg 24 Hour tablet5.72USD tablet
Intuniv 3 mg 24 Hour tablet5.72USD tablet
Intuniv 4 mg 24 Hour tablet5.72USD tablet
Intuniv er 1 mg tablet5.5USD tablet
Intuniv er 2 mg tablet5.5USD tablet
Intuniv er 3 mg tablet5.5USD tablet
Intuniv er 4 mg tablet5.5USD tablet
Tenex 2 mg tablet4.3USD tablet
Tenex 1 mg tablet2.9USD tablet
Guanfacine HCl 2 mg tablet1.22USD tablet
Guanfacine 2 mg tablet1.18USD tablet
Guanfacine HCl 1 mg tablet0.91USD tablet
Guanfacine 1 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5854290 Yes1996-03-212016-03-21Us
US6287599 Yes2001-06-202021-06-20Us
US6811794 Yes2003-01-042023-01-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213-216U.S. Patent 3,632,645.
water solubility1892 mg/LNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP2.28ALOGPS
logP1.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.97 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.63 m3·mol-1ChemAxon
Polarizability21.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,632,645.

General ReferencesNot Available
External Links
ATC CodesC02AC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Guanfacine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Guanfacine.
AbirateroneThe metabolism of Guanfacine can be decreased when combined with Abiraterone.
AcebutololGuanfacine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Guanfacine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Guanfacine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Guanfacine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Guanfacine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Guanfacine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Guanfacine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Guanfacine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Guanfacine.
AliskirenGuanfacine may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Guanfacine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.
AlprenololAlprenolol may increase the hypotensive activities of Guanfacine.
AmbrisentanGuanfacine may increase the hypotensive activities of Ambrisentan.
AmifostineGuanfacine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Guanfacine.
AmineptineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Amineptine.
AmiodaroneGuanfacine may increase the bradycardic activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Guanfacine.
AmitriptylineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Guanfacine.
AmobarbitalAmobarbital may increase the hypotensive activities of Guanfacine.
AmobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Guanfacine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Guanfacine.
AprepitantThe serum concentration of Guanfacine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Guanfacine.
AripiprazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aripiprazole.
ArmodafinilThe metabolism of Guanfacine can be decreased when combined with Armodafinil.
ArotinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Guanfacine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Guanfacine.
AtazanavirThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Guanfacine.
AtomoxetineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Guanfacine.
AzelastineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Guanfacine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azilsartan medoxomil.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Guanfacine.
BarbitalBarbital may increase the hypotensive activities of Guanfacine.
BarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Barbital.
BefunololGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Guanfacine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Guanfacine.
BenmoxinBenmoxin may increase the hypotensive activities of Guanfacine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Guanfacine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Guanfacine.
BepridilGuanfacine may increase the hypotensive activities of Bepridil.
BeractantGuanfacine may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Guanfacine.
BethanidineBethanidine may increase the hypotensive activities of Guanfacine.
BevantololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Guanfacine can be decreased when it is combined with Bexarotene.
BimatoprostBimatoprost may increase the hypotensive activities of Guanfacine.
BisoprololBisoprolol may increase the hypotensive activities of Guanfacine.
BoceprevirThe serum concentration of Guanfacine can be increased when it is combined with Boceprevir.
BopindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Guanfacine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.
BosentanGuanfacine may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the bradycardic activities of Guanfacine.
BretyliumGuanfacine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Brexpiprazole.
BrimonidineGuanfacine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Guanfacine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Guanfacine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Guanfacine.
BufuralolGuanfacine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.
BupranololGuanfacine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Guanfacine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Guanfacine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Guanfacine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Guanfacine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Guanfacine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.
CalfactantGuanfacine may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Guanfacine.
CandoxatrilCandoxatril may increase the hypotensive activities of Guanfacine.
CapecitabineThe metabolism of Guanfacine can be decreased when combined with Capecitabine.
CaptoprilGuanfacine may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Guanfacine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Guanfacine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.
CaroxazoneCaroxazone may increase the hypotensive activities of Guanfacine.
CarteololCarteolol may increase the hypotensive activities of Guanfacine.
CarvedilolGuanfacine may increase the hypotensive activities of Carvedilol.
CeliprololGuanfacine may increase the hypotensive activities of Celiprolol.
CeritinibGuanfacine may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Guanfacine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Guanfacine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Guanfacine.
ChloramphenicolThe metabolism of Guanfacine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Guanfacine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Guanfacine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Guanfacine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Guanfacine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Guanfacine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Guanfacine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.
CholecalciferolThe metabolism of Guanfacine can be decreased when combined with Cholecalciferol.
CilazaprilGuanfacine may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Guanfacine.
CitalopramThe risk or severity of adverse effects can be increased when Guanfacine is combined with Citalopram.
CitalopramThe metabolism of Guanfacine can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Guanfacine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Guanfacine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Guanfacine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Guanfacine.
ClomipramineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clonazepam.
ClonidineClonidine may increase the hypotensive activities of Guanfacine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.
ClotrimazoleThe metabolism of Guanfacine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Guanfacine.
CobicistatThe serum concentration of Guanfacine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Guanfacine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.
ConivaptanThe serum concentration of Guanfacine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Guanfacine can be decreased when combined with Crizotinib.
CrizotinibGuanfacine may increase the bradycardic activities of Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Guanfacine.
CyclizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Guanfacine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Guanfacine.
DabrafenibThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Guanfacine.
DapoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapoxetine.
DarunavirThe serum concentration of Guanfacine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.
DebrisoquinGuanfacine may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Guanfacine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Guanfacine.
DeserpidineGuanfacine may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine.
DesipramineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Guanfacine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Guanfacine.
DexamethasoneThe serum concentration of Guanfacine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Guanfacine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Guanfacine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Guanfacine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Guanfacine.
DiazoxideDiazoxide may increase the hypotensive activities of Guanfacine.
DiclofenamideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Diclofenamide.
DifenoxinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Difenoxin.
DigoxinDigoxin may increase the bradycardic activities of Guanfacine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.
DihydroergotamineThe metabolism of Guanfacine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Guanfacine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Guanfacine.
DiltiazemDiltiazem may increase the hypotensive activities of Guanfacine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.
DinutuximabThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Guanfacine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Guanfacine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Guanfacine.
DonepezilDonepezil may increase the bradycardic activities of Guanfacine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Guanfacine.
DorzolamideDorzolamide may increase the hypotensive activities of Guanfacine.
DosulepinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Dosulepin.
DoxazosinDoxazosin may increase the hypotensive activities of Guanfacine.
DoxepinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Doxepin.
DoxycyclineThe metabolism of Guanfacine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
DoxylamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Guanfacine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
DronedaroneThe metabolism of Guanfacine can be decreased when combined with Dronedarone.
DronedaroneGuanfacine may increase the bradycardic activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Guanfacine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Guanfacine.
DuloxetineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Guanfacine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Guanfacine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Guanfacine.
EfavirenzThe serum concentration of Guanfacine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Guanfacine is combined with Efavirenz.
EfonidipineGuanfacine may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Guanfacine.
EnalaprilatGuanfacine may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Guanfacine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.
EnzalutamideThe serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Guanfacine.
EpoprostenolGuanfacine may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Guanfacine.
ErythromycinThe metabolism of Guanfacine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Guanfacine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Esmirtazapine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Guanfacine.
EsomeprazoleThe metabolism of Guanfacine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Guanfacine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Guanfacine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.
EthanolGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Guanfacine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Guanfacine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Guanfacine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Guanfacine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Guanfacine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Guanfacine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.
EtoperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Guanfacine.
EtravirineThe serum concentration of Guanfacine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.
FelodipineGuanfacine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Guanfacine.
FenfluramineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Guanfacine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Guanfacine.
FingolimodGuanfacine may increase the bradycardic activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.
FloxuridineThe metabolism of Guanfacine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Guanfacine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Guanfacine.
FlunarizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Guanfacine.
FluorouracilThe metabolism of Guanfacine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluoxetine.
FluoxetineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Guanfacine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Guanfacine.
FluvastatinThe metabolism of Guanfacine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Guanfacine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Guanfacine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Guanfacine.
FosphenytoinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Guanfacine.
FurazolidoneFurazolidone may increase the hypotensive activities of Guanfacine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.
Fusidic AcidThe serum concentration of Guanfacine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Guanfacine is combined with gabapentin enacarbil.
GalantamineGalantamine may increase the bradycardic activities of Guanfacine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Guanfacine.
GemfibrozilThe metabolism of Guanfacine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Guanfacine.
GuanabenzGuanabenz may increase the hypotensive activities of Guanfacine.
GuanadrelGuanadrel may increase the hypotensive activities of Guanfacine.
GuanethidineGuanfacine may increase the hypotensive activities of Guanethidine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Guanfacine.
HexamethoniumGuanfacine may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Guanfacine.
HexobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Guanfacine.
HydralazineGuanfacine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Guanfacine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Guanfacine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Guanfacine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
HydroxyzineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Guanfacine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.
IloprostIloprost may increase the hypotensive activities of Guanfacine.
ImatinibThe metabolism of Guanfacine can be decreased when combined with Imatinib.
ImipramineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Guanfacine.
IndenololGuanfacine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Guanfacine can be decreased when combined with Indinavir.
IndoraminGuanfacine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Guanfacine.
IproniazidIproniazid may increase the hypotensive activities of Guanfacine.
IrbesartanGuanfacine may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Guanfacine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Guanfacine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Guanfacine.
IsoniazidThe metabolism of Guanfacine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Guanfacine.
ItraconazoleThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.
IvabradineGuanfacine may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Guanfacine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Guanfacine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Guanfacine.
KetoconazoleThe metabolism of Guanfacine can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Guanfacine.
LacidipineGuanfacine may increase the hypotensive activities of Lacidipine.
LacosamideGuanfacine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.
LanreotideGuanfacine may increase the bradycardic activities of Lanreotide.
LatanoprostLatanoprost may increase the hypotensive activities of Guanfacine.
LeflunomideThe metabolism of Guanfacine can be decreased when combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Guanfacine.
LevetiracetamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.
LevobunololThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Guanfacine.
LevocabastineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocetirizine.
LevodopaGuanfacine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Guanfacine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Guanfacine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Guanfacine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Guanfacine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Guanfacine.
LisinoprilLisinopril may increase the hypotensive activities of Guanfacine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Guanfacine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Guanfacine.
LofexidineGuanfacine may increase the hypotensive activities of Lofexidine.
LopinavirThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Guanfacine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.
LosartanLosartan may increase the hypotensive activities of Guanfacine.
LovastatinThe metabolism of Guanfacine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.
Lu AA21004The risk or severity of adverse effects can be increased when Guanfacine is combined with Lu AA21004.
LucinactantGuanfacine may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Guanfacine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Guanfacine can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.
MacitentanGuanfacine may increase the hypotensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Magnesium Sulfate.
ManidipineGuanfacine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.
MebanazineMebanazine may increase the hypotensive activities of Guanfacine.
MecamylamineMecamylamine may increase the hypotensive activities of Guanfacine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Guanfacine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Guanfacine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Guanfacine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Guanfacine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Guanfacine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Guanfacine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Guanfacine.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Guanfacine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.
MethohexitalMethohexital may increase the hypotensive activities of Guanfacine.
MethohexitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Guanfacine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Guanfacine.
MethsuximideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.
MethyldopaMethyldopa may increase the hypotensive activities of Guanfacine.
Methylene blueMethylene blue may increase the hypotensive activities of Guanfacine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Guanfacine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Guanfacine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methylphenobarbital.
MetipranololGuanfacine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Guanfacine.
MetoprololMetoprolol may increase the hypotensive activities of Guanfacine.
MetyrosineGuanfacine may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.
MibefradilGuanfacine may increase the hypotensive activities of Mibefradil.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.
MifepristoneThe metabolism of Guanfacine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Guanfacine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Guanfacine.
MinaprineMinaprine may increase the hypotensive activities of Guanfacine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
MinoxidilMinoxidil may increase the hypotensive activities of Guanfacine.
MirtazapineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mirtazapine.
MitotaneThe serum concentration of Guanfacine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypotensive activities of Guanfacine.
ModafinilThe serum concentration of Guanfacine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Guanfacine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Guanfacine.
MolsidomineMolsidomine may increase the hypotensive activities of Guanfacine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.
MoxonidineGuanfacine may increase the hypotensive activities of Moxonidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
NabiloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nabilone.
NadololGuanfacine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Guanfacine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.
NebivololGuanfacine may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.
NelfinavirThe metabolism of Guanfacine can be decreased when combined with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nesiritide.
NetupitantThe serum concentration of Guanfacine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Guanfacine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Guanfacine.
NicardipineNicardipine may increase the hypotensive activities of Guanfacine.
NicorandilNicorandil may increase the hypotensive activities of Guanfacine.
NifedipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.
NiguldipineGuanfacine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Guanfacine can be decreased when combined with Nilotinib.
NilvadipineGuanfacine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Guanfacine.
NisoldipineNisoldipine may increase the hypotensive activities of Guanfacine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Guanfacine.
NitrendipineGuanfacine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Guanfacine.
NitroprussideNitroprusside may increase the hypotensive activities of Guanfacine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Guanfacine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Guanfacine.
NortriptylineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nortriptyline.
ObinutuzumabGuanfacine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Guanfacine.
OctreotideOctreotide may increase the bradycardic activities of Guanfacine.
OlanzapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Olanzapine.
OlaparibThe metabolism of Guanfacine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Guanfacine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Guanfacine.
OmeprazoleThe metabolism of Guanfacine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Guanfacine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Guanfacine.
OrphenadrineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Guanfacine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Guanfacine.
OsimertinibThe serum concentration of Guanfacine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.
OxprenololGuanfacine may increase the hypotensive activities of Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Guanfacine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Guanfacine.
PalbociclibThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.
PantoprazoleThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.
ParaldehydeGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Guanfacine.
PargylineGuanfacine may increase the hypotensive activities of Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.
PasireotideGuanfacine may increase the bradycardic activities of Pasireotide.
PenbutololGuanfacine may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.
PentobarbitalPentobarbital may increase the hypotensive activities of Guanfacine.
PentobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pentobarbital.
PentoliniumGuanfacine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Guanfacine.
PerampanelThe risk or severity of adverse effects can be increased when Guanfacine is combined with Perampanel.
PerindoprilPerindopril may increase the hypotensive activities of Guanfacine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Guanfacine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Guanfacine.
PhenelzinePhenelzine may increase the hypotensive activities of Guanfacine.
PheniprazinePheniprazine may increase the hypotensive activities of Guanfacine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Guanfacine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Guanfacine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Guanfacine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Guanfacine.
PhentolaminePhentolamine may increase the hypotensive activities of Guanfacine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Guanfacine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Guanfacine.
PinacidilGuanfacine may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Guanfacine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Guanfacine.
PipotiazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.
PirlindolePirlindole may increase the hypotensive activities of Guanfacine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Guanfacine.
PizotifenThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pizotifen.
PolythiazideGuanfacine may increase the hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.
Poractant alfaGuanfacine may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.
PractololGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleGuanfacine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Guanfacine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Guanfacine.
PrazosinPrazosin may increase the hypotensive activities of Guanfacine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Guanfacine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Guanfacine.
PrimidonePrimidone may increase the hypotensive activities of Guanfacine.
PrimidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Guanfacine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.
PromethazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Promethazine.
PropafenoneGuanfacine may increase the bradycardic activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Guanfacine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Guanfacine.
PropranololPropranolol may increase the hypotensive activities of Guanfacine.
ProtriptylineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Guanfacine.
PyrimethamineThe metabolism of Guanfacine can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Guanfacine.
QuetiapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Guanfacine.
QuinineQuinine may increase the hypotensive activities of Guanfacine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.
RamiprilRamipril may increase the hypotensive activities of Guanfacine.
RanolazineThe metabolism of Guanfacine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Guanfacine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.
RemikirenRemikiren may increase the hypotensive activities of Guanfacine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.
RescinnamineGuanfacine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Guanfacine.
RifabutinThe serum concentration of Guanfacine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Guanfacine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Guanfacine can be decreased when it is combined with Rifapentine.
RiociguatGuanfacine may increase the hypotensive activities of Riociguat.
RisperidoneGuanfacine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Guanfacine.
RitonavirThe serum concentration of Guanfacine can be increased when it is combined with Ritonavir.
RituximabGuanfacine may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Guanfacine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Guanfacine.
RopiniroleGuanfacine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.
RotigotineGuanfacine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Guanfacine.
RuxolitinibRuxolitinib may increase the bradycardic activities of Guanfacine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Guanfacine.
SafrazineSafrazine may increase the hypotensive activities of Guanfacine.
SaprisartanGuanfacine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.
SecobarbitalSecobarbital may increase the hypotensive activities of Guanfacine.
SecobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Guanfacine.
SelexipagGuanfacine may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Guanfacine.
SertralineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sertraline.
SertralineThe metabolism of Guanfacine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guanfacine.
SildenafilSildenafil may increase the antihypertensive activities of Guanfacine.
SiltuximabThe serum concentration of Guanfacine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Guanfacine can be increased when it is combined with Simeprevir.
SitaxentanGuanfacine may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Guanfacine.
SorafenibThe metabolism of Guanfacine can be decreased when combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Guanfacine.
SpiraprilGuanfacine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Guanfacine.
St. John's WortThe serum concentration of Guanfacine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Guanfacine.
SulfadiazineThe metabolism of Guanfacine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.
SuvorexantThe risk or severity of adverse effects can be increased when Guanfacine is combined with Suvorexant.
TadalafilTadalafil may increase the antihypertensive activities of Guanfacine.
TapentadolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tasimelteon.
TelaprevirThe serum concentration of Guanfacine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Guanfacine can be increased when it is combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Guanfacine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.
TemocaprilGuanfacine may increase the hypotensive activities of Temocapril.
TerazosinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Terazosin.
TerlipressinGuanfacine may increase the hypotensive activities of Terlipressin.
TetrabenazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Guanfacine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Guanfacine.
ThalidomideGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Guanfacine.
ThiamylalThiamylal may increase the hypotensive activities of Guanfacine.
ThiamylalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Guanfacine.
ThiopentalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Guanfacine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.
TianeptineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Tianeptine.
TiboloneGuanfacine may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Guanfacine can be decreased when combined with Ticlopidine.
TicrynafenGuanfacine may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Guanfacine.
TimololTimolol may increase the hypotensive activities of Guanfacine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.
TocilizumabThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Guanfacine.
TolazolineTolazoline may increase the hypotensive activities of Guanfacine.
TolbutamideThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.
ToloxatoneToloxatone may increase the hypotensive activities of Guanfacine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.
TorasemideTorasemide may increase the hypotensive activities of Guanfacine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.
TrandolaprilTrandolapril may increase the hypotensive activities of Guanfacine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanfacine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Guanfacine.
TranylcypromineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tranylcypromine.
TravoprostTravoprost may increase the hypotensive activities of Guanfacine.
TrazodoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Guanfacine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.
TrichlormethiazideGuanfacine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Guanfacine.
TrimazosinGuanfacine may increase the hypotensive activities of Trimazosin.
TrimethaphanGuanfacine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.
TrimipramineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.
UdenafilUdenafil may increase the antihypertensive activities of Guanfacine.
UnoprostoneGuanfacine may increase the hypotensive activities of Unoprostone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Guanfacine.
ValsartanValsartan may increase the hypotensive activities of Guanfacine.
VardenafilVardenafil may increase the antihypertensive activities of Guanfacine.
VenlafaxineThe metabolism of Guanfacine can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Guanfacine.
VigabatrinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vilazodone.
VoriconazoleThe metabolism of Guanfacine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Guanfacine.
XylometazolineGuanfacine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Guanfacine.
ZafirlukastThe metabolism of Guanfacine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.
ZiconotideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zimelidine.
ZiprasidoneThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Guanfacine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Guanfacine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Guanfacine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Guanfacine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Guanfacine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF: The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000 Sep;23(3):240-9. [PubMed:10942848 ]
  2. Sagvolden T: The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct. 2006 Dec 15;2:41. [PubMed:17173664 ]
  3. Yuan R, Wu Z, Kostenyuk IA, Burns JK: G-protein-coupled alpha2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase. J Exp Bot. 2005 Jul;56(417):1867-75. Epub 2005 May 31. [PubMed:15928018 ]
  4. Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. [PubMed:11164065 ]
  5. Millan MJ: Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice. Eur J Pharmacol. 1992 May 14;215(2-3):355-6. [PubMed:1356794 ]
  6. Stahl SM: Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar;71(3):223-4. doi: 10.4088/JCP.09bs05899pur. [PubMed:20331927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389 ]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28